Abstract 2421: The role of p53 mutational status and SOX9 suppression in chemotherapy response of ovarian cancer

Noelle L. Cutter Ph.D.
Molloy College, ncutter@molloy.edu

Matthew Lucito

Kim Doyle
Molloy College

Ryan Frank

Follow this and additional works at: https://digitalcommons.molloy.edu/bces_fac

Part of the Chemistry Commons

Recommended Citation
https://digitalcommons.molloy.edu/bces_fac/7

This Abstract is brought to you for free and open access by the Biology, Chemistry, and Environmental Science at DigitalCommons@Molloy. It has been accepted for inclusion in Faculty Works: Biology, Chemistry, and Environmental Studies by an authorized administrator of DigitalCommons@Molloy. For more information, please contact tochtera@molloy.edu, theasin@molloy.edu.
Ovarian cancers are highly heterogeneous where platinum based chemotherapy which induces DNA crosslinking resulting in apoptosis of the cell is the preferred treatment. However, many patients are intrinsically resistant or quickly develop resistance. The Sox factors are a large family of transcription factors that play important roles in tumor development and progression in a variety of human malignancies and diverse developmental processes, but their impact in clinical tumorigenesis is still unclear. An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in a recent issue of Nature. This evidence suggests that epigenetic deregulation, such as methylation, may be a key factor in the onset and maintenance of chemoresistance. Previous microarray analysis results in our lab correctly identified a subset of about 300 genes that when methylated altered the chemoresistance of the ovarian epithelium cells in culture. Of the genes identified in the analysis we further set out to characterize oncogenes and tumor suppressor genes that interact with the guardian of the genome, TP53, to determine if we could elucidate the mechanism by which it increased resistance. Using several in-vitro assays, we determined that the loss of p53 in conjunction with SOX9 decreased the level of apoptosis in response to carboplatin. Furthermore, in cells with mutated p53/SOX9 show an increase in tumorigenesis. Regulation of several pathways with p53 mutations in ovarian cancer might represent a therapy response prediction and could be a future therapeutic target for ovarian cancer. In addition, the crosstalk between p53/SOX9 and epigenetic regulators may present a valid treatment option for increasing carboplatin sensitivity in resistant patients.

Note: This abstract was not presented at the meeting.